[#item_full_content]MASON, Ohio–(BUSINESS WIRE)–Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux. This announcement comes in anticipation of market authorization from the FDA, which Genetesis expects to see later this year. “As we inch ever closer to the FDA granting our De Novo request,